FindTrial
Sign In

Effect of phellodendron Bawei Tablets Combined with Standard Therapy in Improving the Symptoms of Urinary Storage, Sleep Quality and Improving Drug Compliance in Patients with BPH

Effects of phellodendron Bawei Tablets on improving symptoms, sleep quality and drug compliance of patients with BPH during storage period

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046463
Enrollment
Unknown
Registered
2021-05-16
Start date
2019-09-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostatic Hyperplasia

Interventions

Control group:Finasteride + Tamsulosin
Experimental group:standard treatment drugs (Finasteride + Tamsulosin) combined with phellodendron Bawei Tablets

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Aged 45 to 75 years, with a history of BPH/LUTs for more than 6 months, with symptoms of moderate or higher LUTS (IPSS >= 8), maximum urinary flow rate (Qmax) 30ml.

Exclusion criteria

Exclusion criteria: Patients with prostate cancer, urethral strictures, urinary tract infections, as well as patients with previous urethral surgery, absolute indications for surgery, and drug allergies.

Design outcomes

Primary

MeasureTime frame
blood PSA level;Prostate volume;Maximum flow rate;IPSS score;IIEF-5 score;AIS score;—

Countries

China

Contacts

Public ContactHe Yao

Department of Urology, Xiangya Hospital, Central South University

heyao1984@163.com+86 13875855708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026